Crinetics Pharmaceuticals (CRNX) EBITDA (2017 - 2026)

Crinetics Pharmaceuticals' EBITDA history runs 10 years deep, the most recent figure standing at -$140.4 million for Q1 2026.

• In Q1 2026, EBITDA fell 26.01% year-over-year to -$140.4 million; the TTM figure through Mar 2026 stood at -$545.7 million (down 44.86% YoY), while the FY2025 annual figure was -$516.8 million, down 52.5% from the prior year.
• EBITDA for Q1 2026 stood at -$140.4 million, down from -$133.7 million in the prior quarter.
• The five-year high for EBITDA was -$33.8 million in Q1 2022, with the low at -$142.6 million in Q3 2025.
• The 5-year median for EBITDA is -$73.5 million (2024), against an average of -$81.6 million.
• The sharpest annual moves came in 2022 and 2023: EBITDA slumped 64.99% in 2022, then decreased 23.12% in 2023.
• Crinetics Pharmaceuticals' EBITDA stood at -$47.6 million in 2022, then plunged by 31.76% to -$62.7 million in 2023, then plunged by 51.21% to -$94.7 million in 2024, then plunged by 41.08% to -$133.7 million in 2025, then slipped by 5.02% to -$140.4 million in 2026.
• Business Quant data shows CRNX's EBITDA at -$140.4 million in Q1 2026, -$133.7 million in Q4 2025, and -$142.6 million in Q3 2025.